547 studies found for:    Open Studies | "Ovarian Diseases"
Show Display Options
Rank Status Study
21 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Conditions: Malignant Mesothelioma;   Pancreatic Cancer;   Ovarian Tumor;   Triple Negative Breast Cancer;   Endometrial Cancer;   Other Mesothelin Positive Tumors
Intervention: Biological: anti-meso-CAR vector transduced T cells
22 Not yet recruiting A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: avelumab;   Drug: PLD
23 Recruiting Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies
Conditions: Cervical Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Vulvar Carcinoma;   Uterine Corpus Cancer;   Vulvar Carcinoma;   Peritoneal Neoplasms
Interventions: Other: Palliative Therapy;   Other: Palliative Therapy + idiographic
24 Not yet recruiting PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Interventions: Drug: Olaparib;   Drug: Tremelimumab
25 Recruiting The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
Condition: Ovarian Neoplasms
Intervention: Other: Observational cohort
26 Recruiting Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Endometrioid Tumor;   Malignant Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Topotecan Hydrochloride;   Drug: Acetylcysteine
27 Not yet recruiting Cardiovascular Risks and Urinary Albumin Excretion(UAE) in Polycystic Ovarian Syndrome (PCO)
Condition: Urinary Albumin Excretion
28 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
29 Not yet recruiting Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Metastatic Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Solid Neoplasm;   Stage III Mesothelioma;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
30 Not yet recruiting Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Procedure: Cytoreductive surgery;   Drug: IPEC with Cisplatin (75mg/m²);   Drug: IPEC with Cisplatin (120mg/m²);   Drug: Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²);   Drug: HIPEC with Cisplatin (120mg/m²)
31 Not yet recruiting Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Etoposide, Cyclophosphamide, Carboplatin
32 Recruiting Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer
Conditions: Breast Cancer;   Transcriptomes;   Molecular Diagnostic;   Ovarian Cancer
Interventions: Other: collection of a blood sample and breast tissue;   Other: use of a previous blood collection for patients
33 Recruiting Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
Condition: Ovarian Cancer
Interventions: Drug: Cabazitaxel;   Drug: Tocotrienol
34 Recruiting HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Conditions: Ovary Cancer;   Cervix Cancer;   Endometrium Cancer;   Bladder Cancer;   Prostate Cancer (CRPC);   Esophagus Cancer;   Lung Cancer (NSCLC)
Intervention: Drug: HuMax-TF-ADC
35 Not yet recruiting Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )
Conditions: Anovulation;   Polycystic Ovary Syndrome
Interventions: Drug: Letrozole;   Drug: Clomiphene citrate;   Drug: hcg hormone
36 Not yet recruiting Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Paclitaxel;   Radiation: LDWART (Low Dose Whole Abdominal Radiation Therapy)
37 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Conditions: Liver Cancer;   Pancreatic Cancer;   Brain Tumor;   Breast Cancer;   Ovarian Tumor;   Colorectal Cancer;   Acute Myeloid and Lymphoid Leukemias
Intervention: Biological: anti-CD133-CAR vector-transduced T cells
38 Not yet recruiting Sentinel Node Detection in Ovarian Cancer
Conditions: Ovarian Neoplasms;   Sentinel Node
Intervention: Procedure: Injection of radioactive tracer combined with Patent Blue
39 Recruiting Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
Condition: Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Interventions: Biological: BAX69 Single-Route Arm;   Biological: BAX69 Double-Route Arm
40 Recruiting Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: SC-003

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years